Immune checkpoint inhibitors-based therapies for first-line treatment of advanced ovarian cancer with non-BRCAm/HRD-negative: a cost-effectiveness analysis | Synapse
March 3, 2026Open Access
Immune checkpoint inhibitors-based therapies for first-line treatment of advanced ovarian cancer with non-BRCAm/HRD-negative: a cost-effectiveness analysis
Key Points
Cost-effectiveness was assessed for immune checkpoint inhibitors in advanced ovarian cancer.
The analysis indicated that these therapies could be economically viable options.
Utilizing recent economic models, the study focused on patients with non-BRCAm and HRD-negative profiles.
Findings support the idea that effective treatment strategies can also be cost-effective.